Drug-Eluting Stent
Firehawk Stent for Coronary Artery Disease
This trial is testing a new type of stent that releases a drug to keep heart arteries open in patients with certain types of heart disease. The goal is to see if it works as well as current treatments. Drug-eluting stents, which release drugs to prevent artery blockage, have shown promising results and are a major focus in cardiovascular medicine.
P2Y12 Inhibitor
Ticagrelor vs Clopidogrel for Coronary Artery Disease
This trial is testing whether the drug ticagrelor is more effective than clopidogrel in reducing the risk of thrombotic events (blood clots) in patients who are also taking oral anticoagulants (blood thinners). A total of 63 patients will be enrolled and given either ticagrelor or clopidogrel. The trial will assess the pharmacodynamic effects of both drugs to determine which is more effective.
Device
Guided Physiologic Stenting for Coronary Artery Disease
This trial compares two methods for guiding a heart procedure called PCI. It targets patients who need this procedure. One method uses X-ray images, and the other uses pressure measurements to help doctors see where to work during the procedure.
Popular Filters
Trials for CAD Patients
Surgery
Minimally Invasive vs. Conventional Heart Bypass for Coronary Artery Disease
This trial compares a less invasive heart surgery to traditional open-chest surgery in patients with multiple blocked heart arteries. The goal is to see if the less invasive method helps patients recover quicker and improve their quality of life. The less invasive surgery was developed to allow adequate exposure and complete treatment from a small incision without the need for a heart-lung machine.
Genotype-Guided Smoking Cessation Therapy for Coronary Artery Disease
This trial tests if using genetic information to guide smoking cessation treatment can help patients with coronary artery disease quit smoking more effectively. Patients will receive either nicotine replacement therapy or counseling based on their genetic test results.
Procedure
Single vs Multiple Arterial Grafts for Heart Disease
This trial is testing whether using multiple arterial grafts (2+) is better than using a single arterial graft for coronary artery bypass surgery in terms of reducing the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization.
Trials for Cardiovascular Disease Patients
Behavioural Intervention
Smartphone-Based Cardiac Rehab for Cardiovascular Disease
This trial will test if a smartphone app & regular phone calls can help deliver better cardiac rehab to eligible veterans, resulting in better outcomes & decreased hospitalization rates.
Behavioural Intervention
Lifestyle Modification for Coronary Artery Disease
This trial is looking at whether a combined image-treatment regimen of PET + lifestyle modification and lipid-lowering drugs can improve cardiovascular risk score and potentially lower rate of death and other heart problems, compared to current standard of care.
Behavioral Intervention
Risk Reduction Program for Cardiovascular Disease
This trial is designed to better understand how to optimize risk factors for young patients with coronary artery disease, with a focus on gender differences. Patients will be part of a 6 month program that includes education, nutritional and exercise instruction, and psychological support. The goal is to improve quality of life and reduce risk factors.
Behavioural Intervention
Insomnia Therapy for Cardiovascular Disease Improvement
This trial will test if an updated insomnia treatment improves CVD factors & if this is due to improved sleep. 200 participants will get either the treatment or an active control. Results will be measured for CVD factors & sleep.
Phase 3 Trials
Water PET MPI for Coronary Heart Disease
This trial will test a new PET imaging method to help diagnose coronary artery disease (CAD) in 182 participants at 10 sites in the US & Europe. The participants will receive two doses of a special imaging agent and have safety follow-ups.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Canagliflozin for Heart Disease
This trial is a small study to see if a medication called canagliflozin can reduce inflammation in the arteries of patients with heart disease. They will compare the effects of canaglif
siRNA
Inclisiran + Statins for Coronary Artery Disease
This trial is testing inclisiran, an injectable medication, to see if it can reduce plaque in heart arteries of patients with non-obstructive coronary artery disease who have not had previous heart events. Inclisiran works by lowering 'bad' cholesterol levels in the blood.
Procedure
CABG vs PCI for Coronary Artery Disease in Women
This trial compares two procedures for restoring blood flow to the arteries of the heart in women. One procedure involves using a wire mesh tube to open blockages through a small incision in the wrist or groin
Anti-metabolites
Inclisiran for Coronary Artery Disease
This trial aims to study whether controlling cardiovascular risk factors in young adults without known heart disease can reduce the progression of atherosclerosis. The study will enroll 1,600 healthy young adults and randomize
Trials With No Placebo
Surgery
Minimally Invasive vs. Conventional Heart Bypass for Coronary Artery Disease
This trial compares a less invasive heart surgery to traditional open-chest surgery in patients with multiple blocked heart arteries. The goal is to see if the less invasive method helps patients recover quicker and improve their quality of life. The less invasive surgery was developed to allow adequate exposure and complete treatment from a small incision without the need for a heart-lung machine.
Genotype-Guided Smoking Cessation Therapy for Coronary Artery Disease
This trial tests if using genetic information to guide smoking cessation treatment can help patients with coronary artery disease quit smoking more effectively. Patients will receive either nicotine replacement therapy or counseling based on their genetic test results.
Procedure
Single vs Multiple Arterial Grafts for Heart Disease
This trial is testing whether using multiple arterial grafts (2+) is better than using a single arterial graft for coronary artery bypass surgery in terms of reducing the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization.
Procedure
Orbital Atherectomy vs. Angioplasty for Coronary Artery Disease
This trial will compare a high-speed rotating device to remove hard calcium deposits with a traditional method for patients with severely calcified artery issues before placing special stents. The new device is designed to help treat these calcified areas.
View More Related Trials
Frequently Asked Questions
Introduction to coronary artery disease
What are the top hospitals conducting coronary artery disease research?
Coronary artery disease is a prevalent and serious condition that affects millions of people worldwide. In the quest to find innovative treatments and interventions, top hospitals are leading the way with their extensive clinical trial programs. Massachusetts General Hospital in Boston stands out as a pioneer, currently running 11 active trials for coronary artery disease while boasting an impressive history of 50 completed studies since recording their first trial in 2002. Meanwhile, Emory University Hospital in Atlanta has made significant contributions to this field with seven ongoing trials and a total of 33 conducted trials since their inception into coronary artery disease research also in 2002.
In Canada's capital city, Ottawa, the University of Ottawa Heart Institute takes part in advancing knowledge about heart health by conducting six active clinical trials for coronary artery disease along with fifty prior investigations spanning from when they initiated their trailblazing work back in 2000. On the west coast, Cedars-Sinai Medical Center located in Los Angeles has been committed to combating this cardiovascular condition through five ongoing trials and twenty-seven previous explorations after beginning its journey towards understanding it during early phase only just one year later than our founding institution- all starting at around 2001.
Furthermore adding itself among these esteemed institutions comes another pillar: The prestigious University of Pittsburgh Medical Center situated right within Pennsylvania's "Steel City". UPMC endeavors towards improving lives afflicted by coronary artery diseases via actively pursuing five current clinical examinations alongside experience garnered through twenty-three earlier endeavours which began gaining momentum slightly late; having started off merely two years away from now -back then during1994.
These accomplished hospitals demonstrate not only dedication but also remarkable progress achieved thus far on our collective fight against coronary artery disease. Their relentless pursuit of new treatments brings hope to countless individuals affected by this condition globally. As we continue supporting such groundbreaking research, we move closer to discovering more effective strategies for prevention, diagnosis, and treatment -- ultimately saving lives and improving the quality of life for those battling this widespread ailment.
Which are the best cities for coronary artery disease clinical trials?
When it comes to clinical trials for coronary artery disease, several cities are leading the way in research and development. New york City boasts 37 active trials focusing on treatments like Impella CP® and multiple arterial grafting. Boston, Massachusetts follows closely behind with 26 ongoing studies exploring interventions such as IV acetaminophen and Microport Firehawk stent. Atlanta, Georgia also plays a significant role in research with 19 active trials investigating medical/behavioral therapy and orbital atherectomy. Additionally, Gainesville, Florida is conducting 19 trials targeting ACE-I (lisinopril) or ARB (losartan) treatment options alongside other innovations. Lastly, Jacksonville, Florida conducts 14 clinical trials examining interventions like Evolocumab and potent P2Y12 monotherapy. These cities serve as hubs for cutting-edge research that strive to improve the outcomes of individuals affected by coronary artery disease.
Which are the top treatments for coronary artery disease being explored in clinical trials?
The quest for better treatments for coronary artery disease is ongoing, with two promising options currently in clinical trials. Ticagrelor has caught the attention of researchers with its potential benefits, participating in two active trials and making a total of nine all-time trials dedicated to coronary artery disease since its introduction in 2010. Another contender on the horizon is the CardioGard Embolic Protection Cannula, a novel device being investigated in one active trial as well as being listed once previously in 2023. These advancements provide hope for improved outcomes and quality of life for individuals affected by this prevalent cardiovascular condition.
What are the most recent clinical trials for coronary artery disease?
Recent clinical trials have provided valuable insights into the treatment of coronary artery disease, offering potential advancements in patient care. A Phase 4 trial investigating the use of colchicine has shown promise in managing this condition. Another Phase 4 trial focuses on interventions for coronary artery disease, aiming to improve outcomes and quality of life for patients. Additionally, a Phase 1 study explores the effectiveness of rectus sheath block with PIFB as an experimental approach to treating coronary artery disease. Further research is being conducted on dapagliflozin and potent P2Y12 monotherapy as potential therapies for this cardiovascular condition. These studies offer hope for improved treatments and enhanced management strategies moving forward.
What coronary artery disease clinical trials were recently completed?
Recently, several clinical trials have been completed to advance our understanding and treatment of coronary artery disease. Notably, GE Healthcare successfully concluded a trial in January 2022 examining the potential of Flurpiridaz (18F) Injection. In February 2021, the University of Florida wrapped up their investigation into Cangrelor therapy. Additionally, XyloCor Therapeutics' AdVEGFXC1 study reached completion in January 2020. These comprehensive trials contribute valuable insights towards combating this prevalent cardiovascular condition and offer hope for patients worldwide.